Pasithea TherapeuticsAnnounces Pricing of $60 Million Public Offering of Common Stock
Extends cash runway through at least the first half of 2028Led by…
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)…
